Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

NIH 4OTHER 2

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Uterine Cervical Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Oropharyngeal Neoplasms 6Small Cell Lung Carcinoma 4Nasopharyngeal Carcinoma 4Mesothelioma, Malignant 4Urinary Bladder Neoplasms 3Mouth Neoplasms 3Lymphoid Interstitial Pneumonia 3Laryngeal Neoplasms 3Carcinoma 3Adenocarcinoma of Lung 3Vaginal Neoplasms 2Triple Negative Breast Neoplasms 2Tongue Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Hypopharyngeal Neoplasms 2Ganglioneuroblastoma 2Carcinoma, Transitional Cell 2Brenner Tumor 2Urethral Neoplasms 1Ureteral Neoplasms 1Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Solitary Fibrous Tumor, Pleural 1Sinonasal Squamous Cell Carcinoma 1Salivary Gland Neoplasms 1Resectable Intrahepatic Cholangiocarcinoma 1

Interventions

Specimen Handling 6Nivolumab 6Magnetic Resonance Spectroscopy 6Platinum 4Cisplatin 41,2-diaminocyclohexaneplatinum II citrate 4Gemcitabine 3Carboplatin 3Ipilimumab 2Immunoglobulin G 2Disulfides 2CTLA-4 Antigen 2Biopsy 2relatlimab 1fluciclovine F-18 1cemiplimab 1cabozantinib 1atezolizumab 1X-Rays 1Transurethral Resection of Bladder 1Radiotherapy 1Radiation 1Phantoms, Imaging 1Docetaxel 1Cetuximab 1Bevacizumab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × Nasopharyngeal Carcinoma × Platinum × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
156 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06064097 2026-06-03

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

National Cancer Institute (NCI)

Phase 2 Recruiting
50 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
15 enrolled 17 charts
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡